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ABSTRACT
Objectives: Because published utility estimates in multiple
sclerosis (MS) are concentrated in people with moderate to
severe disease severity and focus on speciﬁc types of MS, we
conducted a cross-sectional study of people with MS to esti-
mate the utility associated with disease, functional status as
measured by the Adapted Patient Determined Disease Steps
(APDDS) Scale, and relapse to enhance knowledge of the
association of these factors and utility.
Methods: The study was conducted by a postal question-
naire sent to 12,968 people in a database managed by a UK
charity (the MS Trust). Utility was assessed using the EQ-5D
multiattribute utility scale. The APDDS is closely related to
the more commonly reported Expanded Disability Status
Scale (EDSS).
Results: A total of 2708 (20.9%) questionnaires were
returned and 2048 (15.8%) respondents provided data suit-
able for analysis. The mean age of the sample was 51 years,
and 22.5% of people were aged 60 years or more. Disease
severity was concentrated in people with moderately severe
MS (EDSS 4–6.5), with 21%, 60%, and 19% of people
reporting mild, moderate, and severe disease, respectively.
Results show that disease severity has an inverse relationship
with utility. The mean utility is 0.491. Utility varies between
0.870 and −0.195 for EDSS states 0 and 9. Number of years
since diagnosis, type of disease, and recent relapse status are
also all signiﬁcantly associated with utility.
Conclusions: The results are comparable with previous pub-
lished utility estimates. We have demonstrated a clear rela-
tionship between functional status, disease type, relapse
status, duration of illness, and utility. As a set of coefﬁcients,
the utility estimates we have calculated may be used to com-
pare the quality of life of people with MS with other illnesses
and to inform future economic evaluations in MS.
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Introduction
Multiple sclerosis (MS) is a neurological disease char-
acterized by areas of demyelination (lesions) within the
central nervous system. These lesions affect the normal
functioning of the nerves involved and an accumula-
tion of MS lesions over time result in irreversible phys-
ical and neurological impairment [1]. People with MS
can experience acute exacerbations of symptoms with
periods of stable disease in between (relapsing-remit-
ting MS or RRMS) or there can be a gradual increase
in disability over time with or without acute relapses
(primary progressive MS or PPMS). People with the
remitting form of MS can subsequently experience
progressive disease (secondary progressive MS or
SPMS).
The prevalence of MS across England and Wales is
approximately 110 per 100,000 people (thought to
vary by latitude from 104 per 100,000 on the south
coast of England to 155 per 100,000 in the Scottish
borders) [2]. It is common in young and middle-aged
adults and thus can strike during a person’s most eco-
nomically productive and active years and during the
period when major life decisions are made.
Two disease severity scales are used in the study and
frequently referred to: The clinician rated Expanded
Disability Status Scale (EDSS) [3]; and the self-rated
Adapted Patient Determined Disease Steps (APDDS)
scale, which is a reﬁnement of the Patient Determined
Disease Steps (PDDS) scale [4; G. Kobelt, Pers.
Comm., 2005]. The degree of physical disability and
neurologic impairment in MS is usually measured
quantitatively using the Kurtzke Functional System
scores (FS) and EDSS. The EDSS is based on a stand-
ard neurological examination. Seven functional sys-
tems (pyramidal, cerebellar, brainstem, sensory, bowel
and bladder, visual, and mental functions) are rated.
These ratings are then used in conjunction with obser-
vations and information concerning gait and use of
assistive devices for ambulation to reach an EDSS
score. The FS is an ordinal (or nonlinear) clinical rat-
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ing scale ranging from 0 to 5 or 6. The EDSS is also an
ordinal clinical rating scale ranging from 0 (normal
neurologic examination) to 10 (death due to MS) in
half-point increments. The EDSS is recognized as the
gold standard and is used frequently as an outcome
measure in clinical trials [5]. The APDDS is a reﬁne-
ment of the PDDS [4]. The objective for the develop-
ment of the PDDS was to produce a simple and
reproducible assessment of functional disability in MS
for self-assessment by people with MS that mapped to
the EDSS scale. The PDDS is based on the earlier Dis-
ease Steps scale developed by Hohol et al. [6] Hohol
assessed the Spearman rank correlation coefﬁcient
between Disease Steps and EDSS in 1323 people with
MS and found it to be very strong (0.958), which sup-
ports comparison with EDSS. The APDDS was found
to be equivalent to EDSS, except that APDDS 7, 8, 9,
and 10 equated to EDSS 6.5, 7–7.5, 8–8.5, and 9–9.5,
respectively.
It is clear that MS has a detrimental impact on
health-related quality of life (HRQoL) and utility.
Gruenewald et al. undertook a systematic review of
HRQoL and multiattribute utility scales (MAUS) used
in MS and provided a summary of the literature [7].
MAUSs are measures of health status. They are stand-
ardized multidimensional health state classiﬁcations
with pre-existing preference or utility weights, which
generate a single index score for each state of health
where full health is one and zero is equivalent to death
[8]. MAUSs can have scores of less than zero for health
states regarded as worse than death. MAUSs have
become an important set of instruments for estimating
the health state values used to calculate quality-
adjusted life-years (QALYs) and are widely used in
economic evaluations to value the beneﬁts of health
care. Previous studies have reported MAUS utility esti-
mates for persons with MS in the UK [8,9]; however,
there is a paucity of data in mild disease (EDSS 0–3.5)
and each focuses on a speciﬁc type of MS [9,10].
Despite the debilitating nature of MS, there are
treatments available, albeit ones of modest efﬁcacy.
The Association of British Neurologists (ABN) guide-
lines recommend that two types of treatment (beta
interferon and glatiramer acetate) should be made
available to a well-deﬁned subgroup of people with
MS [11]. The ABN guidelines advocate treatment to
reduce relapses and delay disease progression to a
stage when the treated person is no longer able to
walk.
A cross-sectional study was performed in a large
representative sample of the UK MS population. In this
article, we present the results of the analysis of utility
data collected using a MAUS. The MAUS used is the
EuroQoL 5-Domain self-report questionnaire (Euro-
QoL), incorporating the EQ-5D descriptive system
[12]. The objectives of the analysis are to estimate the
disutility of disease progression for people with MS
and to quantify the disutility associated with an acute
relapse. It is important for health policymakers to
understand how the utility proﬁle of a disease varies
with disease severity so resources can be targeted
appropriately.
Methods
Study Design
A cross-sectional study of people with MS in the UK
was undertaken via a postal survey. The UK-speciﬁc
questionnaire used in the survey was based on an
established tool developed by Kobelt et al., which has
formed the basis of previous cost-of-illness studies and
includes a comprehensive range of resource use to esti-
mate both direct and indirect costs [4,13]. A version
of this questionnaire was veriﬁed against the medical
records of a subset of respondents (n = 202) in the ear-
lier study [13]. The questionnaire was amended and
adapted to the UK setting after consultation with MS
nurses, neurologists and experts at the MS Trust and
MS Society. The questionnaire was checked to ensure
it met the reporting requirements of the Medicines and
Healthcare products Regulatory Agency (MHRA,
Pers. Comm., 2005).
Distribution of Questionnaire
Questionnaires were distributed by the MS Trust
(UK) to its database to ensure names and addresses
remained anonymous. No personal data that would
allow the respondent to be identiﬁed were collected on
the questionnaire. The questionnaire was sent as an
insert to the February 2005 edition of the UK MS Trust
quarterly newsletter “Open Door” (circulation of
12,968). A covering letter explained the details of the
study, and the circumstances in which the data were to
be used. The respondent was required to sign a consent
statement to indicate they had read and agreed with
the terms of the study. It is recognized that some peo-
ple with MS would be unable to complete a question-
naire themselves. Therefore, the instructions indicated
that a carer could complete the questionnaire on behalf
of the person with MS provided they had authority to
do so, in which case the carer was required to sign the
consent statement to indicate this. The completed
questionnaire was returned to the investigators using a
pre-addressed envelope. The number of questionnaires
returned was 2708 (20.9%) and 2048 (15.8%) were
suitable for analysis.
Outcomes Collected
Seven predictive variables were collected to evaluate
the dependent variable, EQ-5D utility. The variables
are shown in Table 1. Disease severity was measured
using APDDS and reported by EDSS strata to aid com-
parison with other studies. Four predictive variables
are used to assess the type of disease. Type of MS
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(PPMS, RRMS, or SPMS) and recent relapse within the
last 3 months are based on a categorical response to a
description within the questionnaire. The disease and
symptom modifying treatments for which data were
collected are shown in Table 1. Respondents were pro-
vided with the generic and trade name of the treat-
ments in the questionnaire.
Utility data were collected using EuroQoL. Utilities
were assigned using the EQ-5D UK value set, which
was obtained from a representative sample of the UK
population using the time–trade-off method [14].
Data Management
Upon receipt, the questionnaire identiﬁer was logged
in an Access database (Microsoft Inc.) and the ques-
tionnaire checked to ensure the consent statement had
been signed. Unsigned questionnaires and question-
naires received after the closing date were not included
in the study.
The questionnaire was processed using specialized
Optical Character Recognition (OCR) and form read-
ing software called FormReader 6.0 (ABBYY Software
House, Moscow, Russia). A sample of original ques-
tionnaire pages was compared with the OCR output
and adjustments made to eliminate character recogni-
tion errors.
Incoming questionnaires were scanned and batch
processed by the OCR and form reading software. An
investigator reviewed any data point that failed the
validation rules established in the OCR and form read-
ing software.
Inter and intraﬁeld validation was again performed
within the Access database using queries to ﬂag illog-
ical or ambiguous data entries. These were checked
against the original questionnaire to rule out data
entry error and records containing invalid data were
marked as censored and excluded from the analysis.
Analysis
Data were analyzed using Stats Direct 1.9.8 (StatsDi-
rect Ltd, Attrinchaw U.K.). A multivariate linear
regression analysis was undertaken to identify the pre-
dictive variables associated with the independent var-
iable, EQ-5D utility. Data are expressed as mean and
95% conﬁdence intervals. Analysis of variance
(ANOVA) was undertaken from the regression and the
multiple correlation coefﬁcient (R2) calculated. Differ-
ences were considered statistically signiﬁcant at a value
of P < 0.05.
Results
The distribution of questionnaires sent to people in
England, Scotland, and Wales was approximately
87%, 8%, and 5%, respectively. It is not known
whether the responses followed a similar distribution.
Table 2 shows the results of the censoring on the
study population used in the analysis. Approximately
Table 1 Variables assessed in the utility analysis
Element Type Variable
Demographics P Sex (male, female)
Years since diagnosis
Education (secondary school, college/sixth form, university/polytechnic, post graduate degree)
Disease severity P Adapted Patient Determined Disease Steps (APDDS) (0–10 scale)*
Type of Disease P Type of MS (PPMS, RRMS, or SPMS)
Recent relapse during prior 3 months (yes or no)
Estimated years since diagnosis as a proxy for disease duration (integer)
Treatment P Currently taking MS treatment (yes or no)
Treatments: glatiramer acetate, interferon β-1a, interferon β-1b
Utility D EQ-5D (derived from EQ-5D descriptive system)
*Reported as EDSS to aid comparison with other studies.
Reference case: No recent relapse, EDSS 0, RRMS, Sex (female), Education (secondary school).
D, dependent variable; MS, multiple sclerosis; P, predictive variable; PPMS, primary progressive MS; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS.
Table 2 Results of censoring on study population
Description Questionnaires n (%)
Questionnaires mailed 12,968 (100.00)
Responses received 2,708 (20.89)
Unsigned or received after deadline 200 (1.54)
Type of MS: multiple selection no selection or “not known” 315 (2.43)
Type of MS: “SPMS” and APDDS < 2 3 (0.02)
Disease severity (APDDS): multiple selection or no selection 12 (0.09)
Utility (EQ-5D): multiple selection or no selection 130 (1.00)
Population for analysis 2,048 (15.79)
Table presented in the order the censoring was carried out. Individual responses could have been censored for more than one reason.
APDDS, Adapted Patient Determined Disease Steps; MS, multiple sclerosis; SPMS, secondary progressive MS.
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Table 3 Demographic and disease information (n = 2048)
Proportion (%)
Demographics
Sex
Male 24.7
Female 74.5
Missing 0.8
Age (mean 51.4) (years)
18–29 1.4
30–39 13.8
40–49 27.0
50–59 35.3
60–69 18.0
70–79 4.2
80 or above 0.3
Education
Secondary school 32.2
College or sixth form 26.5
University or polytechnic degree 29.7
Postgraduate degree 10.1
No answer 1.6
Disease information
Mean age at ﬁrst diagnosis: 38.8 years
Type of MS
RRMS 35.5
SPMS 37.2
PPMS 27.3
EDSS level (disease severity)
EDSS 0–3 21.3
EDSS 4–6.5 59.6
EDSS 7–9.5 19.1
Relapses during last 3 months
Yes 28.9
No 71.1
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; PPMS, primary pro-
gressive MS; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS.
76% (n = 2048) of respondents with a full data set are
suitable for analysis. Censored responses are pre-
dominantly due to a lack of clarity regarding the type
of  MS,  unsigned  or  late  responses,  and  incomplete
or missing data on utility (11.6% (n = 315), 7.4%
(n = 200), and 4.8% (n = 130), respectively).
Table 3 presents demographic and disease informa-
tion on the 2048 respondents in the analysis sample.
Three quarters of respondents are female and the mean
age of the sample is 51.4 years. The sample is well edu-
cated; approximately 40% of respondents have one or
more degrees. First symptoms are reported at 32 years.
The type of MS reported is slightly biased toward
SPMS and RRMS disease, although all three types are
well represented. More than three quarters of the pop-
ulation report moderate or severe disease (EDSS 4 or
greater) and 29% of the sample reported a relapse in
the preceding 3 months.
The distribution of the population by EDSS state
follows a bimodal distribution (Fig. 1) with peak fre-
quencies at EDSS 2 and EDSS 6. Few responses are
available for EDSS states 0, 3, and 9.
The signatories to the survey are predominantly
people with MS. The distribution of signatories
between people with MS, carers or where it is not
reported is approximately 92.5%, 6.4%, and 1.1%,
respectively. A greater proportion of carers are signa-
tories in higher EDSS states, with 44.2% and 75.0% in
EDSS 8 and EDSS 9, respectively. The mean utility for
EDSS 8 reported by carers is signiﬁcantly lower than
that reported by people with MS (P < 0.0001). There is
no signiﬁcant difference between signatories in EDSS
9.
The mean (standard deviation) utility for the study
population is 0.491 (0.320).
There is a signiﬁcant inverse relationship between
EDSS and utility (see Fig. 2 and Table 4). Number of
years since diagnosis as a proxy for disease duration,
type of disease (SPMS), recent relapse status, and edu-
cational status are also all signiﬁcantly correlated with
utility. The PPMS coefﬁcient approaches signiﬁcance
(P = 0.063).
A signiﬁcant association was not found for all
coefﬁcients. In addition to PPMS, sex, and EDSS 1
are not signiﬁcantly different from the reference
case.
Figure 1 Distribution of Expanded Disability
Status Scale (EDSS) states in the study accord-
ing to signatory status. NR, not reported. Half
points on EDSS not shown on graph axis except
at EDSS 6.5.
165
210
309
396
323
193
77
180
151
1628
0
100
200
300
400
0.0 1.0 2.0 3.0 4.0 5.0 6.0 6.5 7.0 8.0 9.0
EDSS
Fr
eq
ue
nc
y
NR Carer Person with MS
Orme et al.58
The predictive power of the regression is high
(R2 = 0.478).
Discussion
This study conﬁrms the impact that MS has on the util-
ity of people with MS. It highlights the decrease in util-
ity associated with an increase in disease severity as
measured by the APDDS. The societal preference from
the UK EQ-5D value sets assesses the utility of people
living with the most severe stages of MS (equivalent to
EDSS 8 and above) as worse than death.
We have also demonstrated that the type of disease
(SPMS), a recent relapse, and length of time since diag-
nosis have an effect on the quality of life of people with
MS. People with SPMS have a lower utility than peo-
ple with RRMS (−0.045). PPMS also has a detrimental
effect on utility compared with RRMS (−0.033)
although the ﬁnding does not quite reach signiﬁcance
(P = 0.063). People with MS who have suffered a
recent relapse also have a signiﬁcant utility decrement
(−0.071). The number of years since diagnosis has a
positive effect on utility, with an approximate utility
gain of 0.01 for every 5-year period with MS. The
small positive correlation could be due to coping strat-
egies adopted by people who have lived with the dis-
ease for a long time.
The ABN recommends treating people with RRMS,
and people with SPMS who are still experiencing fre-
quent relapses, while the person is still able to walk
(EDSS state ≤6.5). Their recommendations are based
on the evidence of treatment effect that is concentrated
in people who entered trials with an EDSS ≤5.5. Our
study demonstrates that large utility losses could be
avoided through delaying progression to EDSS states 7
and beyond. Research into the effects of disease mod-
ifying treatments on delayed disease progression from
moderate to severe disease would help us understand
the utility losses that could be avoided in this group of
people [14].
Utilities of people with RRMS and SPMS have pre-
viously been reported [9,10]. The utilities reported by
Parkin et al. and Forbes et al. compare closely with the
utilities we derived except for those in EDSS 3 (0.71
Parkin et al. compared with 0.57 in the current study)
and EDSS 5 (0.64 Forbes et al. compared with 0.52 in
the current study). The utilities from the Parkin et al.
study included some relapsing patients, however, and
the study by Forbes et al. reported utility values com-
pared with ambulatory categories that we subse-
quently mapped to EDSS state, so it is not possible to
draw a direct comparison with our results.
The average utility of people with MS as measured
in this study appears to be worse than all but one of
the most prevalent conditions assessed by Currie et al.
Figure 2 Relationship between Expanded Dis-
ability Status Scale (EDSS) and utility derived
from EQ-5D using the EuroQoL instrument.
Error bars depict 95% conﬁdence intervals.
Half points on EDSS not shown on graph axis
except at EDSS 6.5.
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Table 4 Coefﬁcients from regression analysis for utility
derived from EQ-5D
Parameter Coefﬁcient
95% CI 
(lower, upper) P-value
Reference case 0.870 (0.782, 0.958) *
EDSS 1–1.5 −0.071 (−0.165, 0.023) 0.138
EDSS 2–2.5 −0.165 (−0.259, −0.072) *
EDSS 3–3.5 −0.296 (−0.398, −0.195) *
EDSS 4–4.5 −0.260 (−0.354, −0.167) *
EDSS 5–5.5 −0.352 (−0.444, −0.260) *
EDSS 6 −0.412 (−0.505, −0.319) *
EDSS 6.5 −0.408 (−0.502, −0.314) *
EDSS 7–7.5 −0.573 (−0.670, −0.477) *
EDSS 8–8.5 −0.919 (−1.017, −0.820) *
EDSS 9–9.5 −1.065 (−1.210, −0.919) *
Recent relapse −0.071 (−0.096, −0.046) *
SPMS −0.045 (−0.076, −0.014) 0.005
PPMS −0.033 (−0.067, 0.002) 0.063
Education: College 0.029 (0.002, 0.055) 0.033
Education: University 0.057 (0.031, 0.082) *
Education: Postgraduate 0.058 (0.022, 0.095) 0.002
Sex: Male 0.017 (−0.007, 0.041) 0.165
Years since diagnosis 0.002 (0.001, 0.003) *
MS treatment — — —
*P < 0.001.
Education: College, college or sixth form; University, university or polytechnic.
—, no association found; CI, conﬁdence interval; EDSS, Expanded Disability Status
Scale; MS, multiple sclerosis; PPMS, primary progressive MS; SPMS, secondary pro-
gressive MS.
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in a hospital setting (people with “other rheumatoid
arthritis” attending a hospital outpatient department)
[15]. Currie et al. evaluated the utilities of 10 most
prevalent conditions in inpatients and outpatients
attending a UK NHS Trust hospital using EQ-5D and
the results have been adapted in Table 5. The observa-
tion is interesting because the MAUS (EQ-5D), coun-
try, and value sets used in both studies are the same;
however, direct comparison should be treated with
caution as the data collection method for each study
differ. If Currie et al. subsequently publish utility esti-
mates for people with MS it will be interesting to note
how the values compare with this study.
The prevalence of the study population by EDSS
state follows a bimodal distribution that has previ-
ously been cited by Richards in a review of several
cross sectional studies [2]. The results are therefore
generalizable to other populations.
There are a number of caveats with the analysis we
performed.
Two reviews have examined the evaluation of qual-
ity of life in MS and reported that EQ-5D has low
coverage of quality of life domains relevant to people
with MS [7,16]. Mitchell et al. reported that EQ-5D
covered three out of 11 domains; Gruenewald et al.
reported coverage of 3 out of 15 domains relevant to
people severely affected by MS (EDSS ≥6). It is likely
that an alternative instrument to EQ-5D, which cov-
ered more domains of relevance to people with MS,
would have resulted in different utilities.
We do not know what effect the alteration of a sin-
gle word in the APDDS has on the correlation between
APDDS and EDSS. The term “stick” replaced “cane”
in APDDS states 4–6. The change was made after con-
sultation with experts and we do not anticipate that it
will have a signiﬁcant impact on the results.
EuroQoL is a self-completed questionnaire, al-
though we allowed carers to complete it where the
person with MS was unable. Bias appears to have been
introduced in EDSS 8–8.5, where carers report a sig-
niﬁcantly worse utility than people with MS. In
another study of people with MS living in a com-
munity setting there was similar discordance noted
between carers and people with MS in reported prob-
lems, where people with MS-reported depression,
mood, and psychosocial issues less frequently than car-
ers as the disease progressed [17].
As with any postal questionnaire study, respondents
were self-selected and a “volunteer effect” has been
previously reported [18]. Volunteers tend to be more
intelligent, open to innovation, and extroverted than a
random sample, although the effect of self-selection on
the results is not known.
The bimodal distribution may be due to the simi-
larity in the wording of APDDS 3 and APDDS 2,
which could cause some respondents to ignore APDDS
3 and choose either APDDS 2 or 4, which are distinctly
different. The APDDS 2 description is, “I have some
noticeable symptoms from my MS (e.g., some muscle
weakness, slight difﬁculties in walking, slight visual
disturbances) but they are minor and have only a small
effect on my lifestyle.” The APDDS 3 description is
similar, “I have symptoms as described above, but I
don’t have any limitations in my walking ability. How-
ever, I do have signiﬁcant problems due to MS that
limit daily activities in other ways.”
The diagnosis of the type of MS and recent relapse
status was made by the respondent and was not based
Table 5 A comparison of the utility of people with MS and other prevalent conditions
ICD10 Disease Mean SD N Setting
M06 Other rheumatoid arthritis 0.432 0.310 120 OP
– Multiple sclerosis (PPMS, RRMS, and SPMS) 0.491 0.320 2408 —
I25 Chronic ischemic heart disease 0.558 0.317 146 OP
R10 Abdominal and pelvic pain 0.576 0.350 74 OP
I20 Angina pectoris 0.576 0.306 284 IP
R07 Pain in throat and chest 0.589 0.346 472 IP
I21 Acute myocardial infarction 0.610 0.336 251 IP
I48 Atrial ﬁbrillation and ﬂutter 0.614 0.316 189 IP
I25 Chronic ischemic heart disease 0.636 0.293 789 IP
R10 Abdominal and pelvic pain 0.670 0.325 337 IP
K21 Gastroesophageal reﬂux disease 0.671 0.301 216 IP
H26 Other cataract 0.672 0.286 748 IP
E11 Noninsulin-dependent diabetes mellitus 0.674 0.287 159 OP
K50 Crohn’s disease [regional enteritis] 0.692 0.293 73 OP
I10 Essential (primary) hypertension 0.694 0.306 82 OP
N95 Menopausal and other perimenopausal disorders 0.703 0.317 103 OP
K80 Cholelithiasis 0.709 0.305 192 IP
C61 Malignant neoplasm of prostate 0.718 0.278 83 OP
C44 Other malignant neoplasms of skin 0.726 0.267 273 IP
K51 Ulcerative colitis 0.787 0.235 61 OP
N92 Excessive, frequent, and irregular menstruation 0.804 0.250 116 OP
All conditions other than MS adapted from Currie et al. (2005) (tables 5 and 6) [15].
IP, inpatient; MS, multiple sclerosis; OP, outpatient; PPMS, primary progressive MS; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS.
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on a deﬁnitive clinical diagnosis and this could result
in some miscategorization.
The coefﬁcient calculated for recent relapse should
not be used to infer a total utility loss associated with
relapse. A longitudinal study would be required to
determine this total utility loss.
Conclusion
Our results show that people with MS have a quality
of life that deteriorates as the disease progresses until
severe disability occurs in what some have described as
a state worse than death at EDSS 8. SPMS and recent
relapse are both indicators of further utility loss. Peo-
ple with MS that responded to the survey appear to
live in a utility state that is equivalent or somewhat
worse than all but one of the most prevalent conditions
admitted to a UK inpatient or outpatient setting.
Research into existing and future MS treatments
should measure the effect of treatment on the utility of
people with MS to better help patients, clinicians, and
health-care decision-makers evaluate the interventions.
The designers of studies should consider evaluating
treatments in greater numbers of people with moderate
states of disability and impairment (i.e., EDSS 4, 5, and
6), because if the disease could be delayed in these peo-
ple large then losses in utility could be avoided in EDSS
≥6.5.
Finally, the utility results have ﬁlled a gap in our
knowledge and could be used in future economic eval-
uations in MS.
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